Table 3.
Analysis for LST decision in COVID-19 during the first wave of pandemic.
| Adjusted OR (95%CI; p-value) | |
|---|---|
| Composite biological criteria (D-dimer, NT-pro-BNP/BNP and creatinine) | |
| 0 Criteria | – |
| 1 Criteria | 2.75 (0.83–10.99, p = 0.117) |
| 2 Criteria | 3.50 (1.07–13.84, p = 0.050) |
| 3 Criteria | 4.67 (1.79–13.80, p = 0.003) |
| Age | 1.02 (0.99–1.05, p = 0.126) |
| High blood pressure | 1.14 (0.57–2.25, p = 0.707) |
| Ischemic stroke | 2.23 (0.99–5.25, p = 0.059) |
| Kidney failure | 1.42 (0.72–2.82, p = 0.306) |
| Thromboembolism disease | |
| None | – |
| Arterial thrombosis | 2.45 (0.98–6.97, p = 0.068) |
| Venous thrombosis | 1.41 (0.97–2.06, p = 0.074) |
| History of cardiomyopathy | 1.75 (0.82–3.84, p = 0.154) |
| History of atrial fibrillation | 0.89 (0.42–1.86, p = 0.754) |
| Qsofa ≥2 | 0.99 (0.56–1.76, p = 0.980) |
| ARBs | 0.31 (0.16–0.61, p = 0.001) |
| Diuretic medication | 1.08 (0.57–2.05, p = 0.824) |
Logistic regression model to assess the association between LST decision and the composite biological criteria (D-dimer, NT-pro-BNP/BNP, and creatinine) adjusted on potential clinical confounder.